Stroke Thrombectomy: Current Indications and Results

Philipp Taussky, MD
Co-Director Brain Aneurysm Institute
Surgical Co-Director Comprehensive Stroke Center
Beth Israel Deaconess Medical Center







Disclosures:



Consultant:

Medtronic

Stryker

Cerenovus

Avail


Pipeline proctor > 100 cases





Major Challenges

- q Less than 10% of stroke victims receive treatment
- q Challenges include:
 - Øpublic awareness,
 - Øemergency medical services
 - Øaccess to medical care and equipment
- q Slow progress in scientific achievements and treatments



CONTENTS

- 1 From the Greek Period to 1915, 3
- 2 Collateral Circulation, 29
- 3 Arteriography, 57
- 4 Cerebrovascular Surgery, 77
- 5 Medical Management of Cerebrovascular Disease, 104
- 6 Noninvasive Vascular Studies, 122
- 7 Hypertension and Stroke, 150
- 8 Epidemiology of Stroke, 169
- 9 Well-Known Persons Who Have Suffered Strokes, 177
 Index, 203



History of Treatment Options

- ☐ Historically, stroke treatment centered on rehabilitation and later on prevention
- ☐ Only since 1990s systematic studies and efforts aimed at revascularization and 'clot-busting'
- ☐ Since 1990s i.v. tPA has become standard of care and aim of stroke treatment from rehab to revascularization



HOME | SUBSCRIBE | CURRENTISSUE | PASTISSUES | COLLECTIONS | HELP | Search NEJIM

GO: Maria Commen

Please sign in for full text and personal services.

TABLE OF CONTENTS

≠Previous

Volume 333 December 14, 1995 Number 24

Next*

ORIGINAL ARTICLES

Tissue Plasminogen Activator for Acute Ischemic Stroke

The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group

Abstract | Full Text | PDF

Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke R. Kay and Others

Cancer in the Parents of Children with Cancer J. H. Olsen and Others

Medication Use and the Risk of Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis J.-C. Roujeau and Others

EDITORIALS

Acute Stroke - On the Threshold of a Therapy?

G. J. del Zoppo

Is There an Inherited General Susceptibility to Cancer?

T. I.A. Sørensen


SOUNDING BOARD

To Stay or Not to Stay? That is the Question V. M. Parisi and B. A. Meyer


CORRESPONDENCE

Magnesium Sulfate versus Phenytoin for the Prevention of Eclampsia

Amiodarone in Congestive Heart Failure



What does all this mean for a typical group of 100 stroke patients?




Suppose that 25 would have had a good stroke outcome (mRS 0-1) without rt-PA and 6 would have died within the first week

If they had all been given rt-PA within 3 hours...


...the number recovering rises to about 35 ...but 2 extra would die from ICH within 7 days

8



Smith WS, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: Results of the MERCI trial. *Stroke*. 2005; 36: 1432–1438.


MERCI



Smith WS, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: Results of the MERCI trial. *Stroke*. 2005; 36: 1432–1438.

MODERN STROKE TRIALS 2015

☐ 11 years to improve device design and ultimately prove efficacy





Game changing trials in 2015




with Perfusion-Imaging Selection


B.C.V. Campbell, P.J. Mitchell, T.J. Kleinig, H.M. Dewey, L. Churilov, N. Yassi, B. Yan, R.J. Dowling, M.W. Parsons, T.J. Oxley, T.Y. Wu, M. Brooks, M.A. Simpson, F. Miteff, C.R. Levi, M. Krause, T.J. Harrington, K.C. Faulder, B.S. Steinfort, M. Priglinger, T. Ang, R. Scroop, P.A. Barber, B. McGuinness, T. Wijeratne, T.G. Phan, W. Chong, R.V. Chandra, C.F. Bladin, M. Badve, H. Rice, L. de Villiers, H. Ma, P.M. Desmond, G.A. Donnan, and S.M. Davis, for the EXTEND-IA Investigators*


Randomized Clinical Trials 2015

Good Outcome (%) Rankin 0-2 at 90 days




	MR CLEAN	REVASCAT	ESCAPE	SWIFT PRIME	EXTEND-IA
	P<0.5	P<0.05	P<0.001	P<0.001	P<0.01
Endo- vascular	33%	44%	53%	60%	71%
Control	19%	28%	29%	36%	40%





What does all this mean for a typical group of 100 stroke patients




Suppose that 35 patients would have had a good stroke outcome (mRS 0 to 2) at 3 months and 12 would have died after receiving IVT

If they have been given endovascular treatment...

... the number recovering rises to 60...


... 3 less patients would die within 3 months

Extending the Time Window: 6-24 hours




DEFUSE-3

DAWN TRIAL: 6-24 hour window



Nogueira RG et. al; DAWN Trial Investigators. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018 Jan 4;378(1):11-21. doi: 10.1056/NEJMoa1706442. Epub 2017 Nov 11. PMID: 29129157.


DEFUSE-3 TRIAL: 6-18 hour window





Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials


Mayank Goyal, Bijoy K Menon, Wim H van Zwam, Diederik W J Dippel, Peter J Mitchell, Andrew M Demchuk, Antoni Dávalos, Charles B L M Majoie, Aad van der Lugt, Maria A de Miquel, Geoffrey A Donnan, Yvo B W E M Roos, Alain Bonafe, Reza Jahan, Hans-Christoph Diener, Lucie A van den Berg, Elad I Levy, Olvert A Berkhemer, Vitor M Pereira, Jeremy Rempel, Mònica Millán, Stephen M Davis, Daniel Roy, John Thornton, Luis San Román, Marc Ribó, Debbie Beumer, Bruce Stouch, Scott Brown, Bruce C V Campbell, Robert J van Oostenbrugge, Jeffrey L Saver, Michael D Hill, Tudor G Jovin, for the HERMES collaborators

www.thelancet.com Vol 387 April 23, 2016









Goyal M, et. al HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016 Apr 23;387(10029):1723-31. doi: 10.1016/S0140-6736(16)00163-X. Epub 2016 Feb 18. PMID: 26898852.

Number Needed to Treat

In order to have one additional patient be independent at 90 days

MR CLEAN

ESCAPE

ชิชิชิชิ

EXTEND-IA

 $\mathring{\mathbb{T}}\mathring{\mathbb{T}}$

SWIFT PRIME

PRIMARY PCI VS. THROMBOLYSIS FOR STEMI: PREVENTION OF DEATH/MI/



Three Burning Questions



tPA yes/no?


Large Core?

Large Vessel Occlusion

Techniques

Straight to Angio?

Three Burning Questions



tPA yes/no?

Large Core?

Large Vessel Occlusion

Techniques

Straight to Angio?

Beth Israel Deaconess Medical Center

HARVARD MEDICAL SCHOOL TEACHING HOSPITAL

Effect of Mechanical Thrombectomy Without vs with Intravenous Thrombolysis on Functional Outcome Among Patients With Acute Ischemic Stroke The SKIP Randomized Clinical Trial

Kentaro Suzuki, MD, PhD; Yuji Matsumaru, MD, PhD; Masataka Takeuchi, MD; Masafumi Morimoto, MD, PhD; Ryuzaburo Kanazawa, MD, PhD; Yohei Takayama, MD; Yuki Kamiya, MD, PhD; Keigo Shigeta, MD, PhD; Seiji Okubo, MD, PhD; Mikito Hayakawa, MD; Norihiro Ishii, MD, PhD; Yorio Koguchi, MD, PhD; Tomoji Takigawa, MD, PhD; Masato Inoue, MD, PhD; Hiromichi Naito, MD; Takahiro Ota, MD, PhD; Teruyuki Hirano, MD, PhD; Noriyuki Kato, MD, PhD; Toshihiro Ueda, MD, PhD; Yasuyuki Iguchi, MD, PhD; Kazunori Akaji, MD, PhD; Wataro Tsuruta, MD, PhD; Kazunori Miki, MD, PhD; Shigeru Fujimoto, MD, PhD; Tetsuhiro Higashida, MD, PhD; Mitsuhiro Iwasaki, MD; Junya Aoki, MD, PhD; Yasuhiro Nishiyama, MD, PhD; Toshiaki Otsuka, MD, PhD; Kazumi Kimura, MD, PhD; for the SKIP Study Investigators

JAMA January 19, 2021 Volume 325, Number 3


Randomized clinical trial of 204 patients

A favorable functional outcome **59.4% of patients with mechanical thrombectomy alone** and in **57.3% of those randomized to combined intravenous thrombolysis plus mechanical thrombectomy** (odds ratio, 1.09 [95% confidence limit below the noninferiority margin of 0.74]).

The findings **failed** to demonstrate **noninferiority** of mechanical thrombectomy alone but also did not allow a conclusion of **inferiority**.

Beth Israel Deaconess Medical Center





	MT alone	MT + tPA	P value
Any hemorrhage at 36 hrs	34%	51%	0.2
Symptomatic hemorrhage (NINDS criteria)	8%	12%	.48




JAMA Neurology | Original Investigation


Direct to Angiography Suite Without Stopping for Computed Tomography Imaging for Patients With Acute Stroke A Randomized Clinical Trial

Manuel Requena, PhD; Marta Olivé-Gadea, MD; Marian Muchada, PhD; David Hernández, MD; Marta Rubiera, PhD; Sandra Boned, PhD; Carlos Piñana, MD; Matías Deck, MD; Álvaro García-Tornel, MD; Humberto Díaz-Silva, MD; Noelia Rodriguez-Villatoro, PhD; Jesús Juega, MD; David Rodriguez-Luna, PhD; Jorge Pagola, PhD; Carlos Molina, PhD; Alejandro Tomasello, MD; Marc Ribo, MD, PhD

JAMA Neurology September 2021 Volume 78, Number 9









The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

APRIL 7, 2022

VOL. 386 NO. 14

Endovascular Therapy for Acute Stroke with a Large Ischemic Region


S. Yoshimura, N. Sakai, H. Yamagami, K. Uchida, M. Beppu, K. Toyoda, Y. Matsumaru, Y. Matsumoto, K. Kimura, M. Takeuchi, Y. Yazawa, N. Kimura, K. Shigeta, H. Imamura, I. Suzuki, Y. Enomoto, S. Tokunaga, K. Morita, F. Sakakibara, N. Kinjo, T. Saito, R. Ishikura, M. Inoue, and T. Morimoto


Yoshimura S, et. al. Endovascular Therapy for Acute Stroke with a Large Ischemic Region. N Engl J Med. 2022 Apr 7;386(14):1303-1313. doi: 10.1056/NEJMoa2118191. Epub 2022 Feb 9. PMID: 35138767.











Yoshimura S, et. al. Endovascular Therapy for Acute Stroke with a Large Ischemic Region. N Engl J Med. 2022 Apr 7;386(14):1303-1313. doi: 10.1056/NEJMoa2118191. Epub 2022 Feb 9. PMID: 35138767.

Main Advances: Novel Tools










First pass effect: The New Outcome







Yeo L et. al.. Evidence-Based Updates to Thrombectomy: Targets, New Techniques, and Devices. Front Neurol. 2021 Sep 9;12:712527. doi: 10.3389/fneur.2021.712527. PMID: 34566856; PMCID: PMC8459011.





Main Advances: Novel Tools











train 10 mi puncture: 0862 access: 6865 on clot: 0819

Tici: 3 Solitaire Commission

Beth Israel Deaconess Medical Center

Conclusion



- Stroke has become a surgical disease to a large degree
- **Indications** are constantly **expanding** in terms of time window, core volume and mismatch ratio, including distal branches
- **Device advances** are continuously improving technical aspects resulting in improved first-pass effects
- Questions remain regarding: skip tPA, medium vessel occlusions, largs cores
- Next big frontiers: AI, expanding stroke networks, straight to angio, training



Beth Israel Deaconess Medical Center

THANK YOU



ptaussky@bidmc.harvard.edu

Cell: 801-688-2668

